Systemic therapies for salivary gland cancer: Adenoid cystic carcinoma. REFCOR recommendations by the formal consensus method

被引:5
作者
Ferrand, F. -R. [1 ,2 ,3 ]
Even, C. [1 ]
Chabrillac, E. [4 ]
Thariat, J. [5 ]
Fakhry, N. [6 ]
Vergez, S. [4 ,7 ]
Bensadoun, R. -J. [8 ]
Sarradin, V. [9 ]
Digue, L. [10 ]
机构
[1] Inst Gustave Roussy, Dept Oncol Med, Villejuif, France
[2] Inst Rech Biomed Armees, Bretigny Sur Orge, France
[3] French Armed Forces Biomed Res Inst, F-91220 Bretigny Sur Orge, France
[4] Inst Univ Canc Toulouse Oncopole, Dept Chirurg, Toulouse, France
[5] Ctr Francois Baclesse, Dept Radiotherapie, Caen, France
[6] Hop La Conception, AP HM, Dept ORL & Chirurg Cerv Faciale, Marseille, France
[7] Univ Toulouse III Paul Sabatier, Dept Chirurg ORL & Cerv Faciale, CHU Toulouse Larrey, Toulouse, France
[8] Clin St Georges, Ctr Haute Energie, Nice, France
[9] Inst Univ Canc Toulouse Oncopole, Dept Oncol Med, Toulouse, France
[10] Hop St Andre, Dept Oncol Med, Bordeaux, France
关键词
Adenoid cystic carcinoma; Locally advanced stage; Metastatic stage; Systemic therapy; Chemotherapy; PHASE-II TRIAL; CISPLATIN COMBINATION CHEMOTHERAPY; RECURRENT; HEAD; NECK; CYCLOPHOSPHAMIDE; 5-FLUOROURACIL; DOXORUBICIN; MITOXANTRONE; PLATINUM;
D O I
10.1016/j.anorl.2023.11.009
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Objective: To determine the therapeutic indications for systemic medical treatment in the management of adenoid cystic carcinoma (ACC) according to the clinical situation. Materials and methods: The French Network of Rare Head and Neck Tumors (REFCOR) formed a steering group, which drafted a narrative review of the literature published on Medline and proposed recommendations. The level of adherence to the recommendations was then assessed by a rating group, according to the formal consensus method. Results: ACCs are rare tumors and there is currently insufficient evidence to indicate chemotherapy at the localized stage. At the metastatic stage, progression is often slow. In case of oligometastatic ACC, local treatment should be discussed. The most often indolent nature of polymetastatic ACC can allow management by active surveillance. Molecular screening is recommended, for abnormalities potentially accessible to targeted therapy. Conclusion: ACCs are rare tumors for which there are currently few effective medical treatments. It is therefore recommended to include patients in clinical trials. (c) 2023 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:286 / 291
页数:6
相关论文
共 64 条
[1]   Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non-adenoid cystic carcinoma malignant tumors of the salivary glands [J].
Agulnik, Mark ;
Cohen, Ezra W. E. ;
Cohen, Roger B. ;
Chen, Eric X. ;
Vokes, Everett E. ;
Hotte, Sebastien J. ;
Winquist, Eric ;
Laurie, Scott ;
Hayes, D. Neil ;
Dancey, Janet E. ;
Brown, Shirley ;
Pond, Gregory R. ;
Lorimer, Ian ;
Daneshmand, Manijeh ;
Ho, James ;
Tsao, Ming-Sound ;
Siu, Lillian L. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) :3978-3984
[2]   CISPLATIN, EPIRUBICIN AND 5-FLUOROURACIL COMBINATION CHEMOTHERAPY FOR RECURRENT CARCINOMA OF THE SALIVARY-GLAND [J].
AIROLDI, M ;
PEDANI, F ;
BRANDO, V ;
GABRIELE, P ;
GIORDANO, C .
TUMORI, 1989, 75 (03) :252-256
[3]  
Airoldi M, 1998, B CANCER, V85, P892
[4]  
Airoldi M, 2000, ANTICANCER RES, V20, P3781
[5]  
Airoldi M, 2001, CANCER, V91, P541, DOI 10.1002/1097-0142(20010201)91:3<541::AID-CNCR1032>3.0.CO
[6]  
2-Y
[7]  
ALBERTS DS, 1981, CANCER-AM CANCER SOC, V47, P645, DOI 10.1002/1097-0142(19810215)47:4<645::AID-CNCR2820470404>3.0.CO
[8]  
2-A
[9]   PRELIMINARY EXPERIENCE WITH CHEMOTHERAPY IN ADVANCED SALIVARY-GLAND NEOPLASMS [J].
BELANI, CP ;
EISENBERGER, MA ;
GRAY, WC .
MEDICAL AND PEDIATRIC ONCOLOGY, 1988, 16 (03) :197-202
[10]  
Chabrillac E, 2024, Eur Ann Otorhinolaryngol Head Neck Dis, DOI [10.1016/j.anorl.2023.11.003, DOI 10.1016/J.ANORL.2023.11.003]